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REVIEW
Abstract: Leptin, a peptide discovered more than 10 years ago, decreases food intake and
increases sympathetic nerve activity to both thermogenic and nonthermogenic tissue. Leptin
was initially believed to be an anti-obesity hormone, owing to its metabolic effects. However,
obese individuals, for unknown reasons, become resistant to the satiety and weight-reducing
effect of the hormone, but preserve leptin-mediated sympathetic activation to nonthermogenic
tissue such as kidney, heart, and adrenal glands. Leptin has been shown to influence nitric
oxide production and natriuresis, and along with chronic sympathetic activation, especially
to the kidney, it may lead to sodium retention, systemic vasoconstriction, and blood pressure
elevation. Consequently, leptin is currently considered to play an important role in the
development of hypertension in obesity.
Keywords: leptin, renal sympathetic nerve activity, blood pressure, obesity, selective leptin
resistance, nitric oxide, natriuresis
Introduction
Obesity is considered a world health problem especially in western industrialized
countries, where its incidence and prevalence are rising steadily, along with several
comorbities associated with it, such as hypertension, diabetes, dyslipidemia,
atherosclerosis, and chronic renal failure. Among these, hypertension – a very
important cardiovascular risk factor – has been observed in roughly 50% of obese
individuals, which has led researchers to consider obesity as one of the most common
causes of hypertension. Hence, hypertension in obesity has become a topic of extensive
ongoing research.
Now, several mechanisms have been implicated in the association between obesity
and hypertension, including activation of sympathetic nervous system, abnormal renal
sodium handling, insulin resistance, and physical compression of the kidney (Haynes
et al 1998).
In this respect, sympathetic activation appears to mediate at least part of the
obesity-induced hypertension, and leptin, the adipocyte-derived hormone, has recently
been postulated as one of the possible causes of this sympathetic activation in obesity.
Leptin is a 167 amino acid hormone discovered in 1994 that is almost exclusively
produced by adipose tissue and possibly secreted by a constitutive mechanism. The
effects of this peptide are mediated by receptors (Ob-R), most of them located in the
hypothalamus, belonging to the class l cytokine receptor family. As of yet, 6 leptin
receptor isoforms are known (Ahima and Flier 2000).
Leptin is considered a homeostatic hormone regulating food intake and body
weight. Acting on the hypothalamic nuclei, leptin decreases appetite, and increases
energy expenditure through sympathetic activation, which consequently decreases
adipose tissue mass and body weight. The hormone levels are decreased during fasting
and increased after several days of overfeeding as an effort to help regulate energy
balance in humans. Due to latter homeostatic control mechanism, leptin is an anti-
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obesity hormone, based on the hypothetical fact that high
leptin levels would prevent the occurrence of obesity.
Unfortunately, this is not the case, and so the strong
correlation between serum leptin levels and body fat mass
found in obese individuals now suggests the existence of
an endogenous leptin-resistant mechanism in obesity
(Considine et al 1996).
In addition to regulating food intake and adipose tissue
mass, leptin has been found to be involved in cardiovascular
physiological processes like sympathetic nerve system
activation, renal hemodynamics, blood vessel tone, and
blood pressure. This review will focus on the leptin-mediated
sympathetic activation and its relevance to the mechanism
of obesity-related hypertension.
Concept of selective leptin
resistance
As stated above, obesity is associated with high leptin levels,
reflecting the increased amount of adipose tissue in obese
individuals. As a consequence, it has been postulated that
the apparent loss of the anorexic and weight-reducing effects
of leptin in obesity, is a result of a leptin-resistance
mechanism. Nevertheless, obesity is associated with
increased sympathetic nerve activity, and leptin has been
proven to participate in autonomic nervous system control,
in part, by increasing renal sympathetic nerve activity
(RSNA). Therefore, it is contradictory that, in the presence
of a leptin resistance state, the hormone can contribute to
the sympathetic activation seen in obesity. This has led to
the novel concept of selective leptin resistance, in which
resistance appears to be primarily limited to the metabolic
(satiety and weight-reducing) actions of leptin, sparing the
renal sympathetic activation effects. This concept has
emerged from observations made first in agouti yellow obese
(Ay) mice (Correia et al 2002; Rahmouni et al 2002), and
corroborated recently in a diet-induced obesity model
(Rahmouni et al 2005). In these studies, leptin administered
peripherally produced increase in RSNA in both obese and
lean mice, but failed to decrease food intake and body weight
in the obese mice to a similar degree as it did in their lean
littermates. Interestingly, this same effect was observed
when leptin was injected into the lateral ventricle of the
brain (Rahmouni et al 2002, 2005). Here, leptin increased
RSNA again, without changing significantly food intake and
body weight in Ay and diet-induced obese mice, as compared
with their respective lean littermates. These latter studies
also served to demonstrate that is unlikely that leptin
resistance is due to an impaired leptin transport mechanism
across the blood–brain barrier as intracerebroventricular
administration of the hormone also failed to enhance food
intake and weight loss. Moreover, the increased RSNA
achieved by central leptin administration was not
accompanied by changes in plasma leptin levels, suggesting
that leptin-induced RSNA was centrally-mediated.
In agreement with these observations, Munzberg et al
(2004) recently described that leptin resistance is not global
within the hypothalamus, and found that the arcuate nuclei,
which contains leptin-mediated anorexigenic neurons,
becomes resistant to leptin in very early stages of diet-
induced obesity in mice. On the contrary, other hypothalamic
and extrahypothalamic sites appear to continue relatively
sensitive to the actions of leptin, including the ventromedial
hypothalamic nuclei, which has been previously shown to
mediate leptin-induced sympathetic nerve activation (Satoh
et al 1999).
This hypothesis, however, must be proved in human
studies as well, and if true, it would help explain how leptin
could contribute to sympathetic activation and hypertension
despite the fact that there is resistance to the satiety and
weight-reducing effects of leptin in obesity.
Renal effects of leptin: the role of
the sympathetic nervous system
and nitric oxide
In the kidney, leptin may affect blood pressure mainly by
two opposing ways: the first is through renal sympathetic
activation (Haynes, Sivitz, et al 1997), and the second is
related to nitric oxide (NO) synthesis (Vecchione et al 2002).
The renal effect of leptin also depends on the exposure time
to the hormone. As it has been observed, acutely
administered leptin usually does not increase blood pressure
in animal or human studies, but when given for longer
periods of time, leptin does elevate blood pressure in animal
models.
Acute effects
Traditionally, obesity-induced renal sympathetic
activation has been thought to contribute to the
development of hypertension by enhancing sodium
retention, since renal denervation attenuates the
antinatriuretic and hypertensive effect of obesity in dogs
(Kassab et al 1995). Although systemic administration
of leptin stimulates sympathetic nerve activity to the
kidney (Haynes, Morgan, et al 1997), if infused for shortVascular Health and Risk Management 2006:2(2) 165
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periods of time, leptin produces increased sodium
excretion and urine output with no changes in blood
pressure in lean animals (Jackson and Li 1997; Villarreal
et al 1998; Beltowski, Wojcicka, Gorny, et al 2002;
Beltowski, Jochem, et al 2004). The increased natriuresis
and fractional sodium excretion are not accompanied by
substantial changes in glomerular filtration rate or the
renin–aldosterone axis suggesting a decreased sodium
tubular transport. Beltowski, Wojcicka, et al (2002)
described a decreased sodium–potassium exchanger (Na/
K-ATPase) activity in the renal medulla following acute
leptin administration. New evidence suggests that leptin
stimulates systemic NO release which opposes the pressor
and antinatriuretic effect of leptin-induced sympathetic
activation (Beltowski, Wojcicka, Borkowska, et al 2002;
Beltowski, Jochem, et al 2004). In this regard, Vecchione
et al (2002) demonstrated that leptin stimulates NO
production in endothelial cells and blood vessels. In other
studies, leptin evoked a hypotensive effect when the
sympathetic nervous system output was blocked
pharmacologically, implying a likely leptin-mediated
vasorelaxant effect (Fruhbeck 1999; Lembo et al 2000).
It has been demonstrated that endogenously-produced
NO inhibits renal sodium reabsorption in most of the tubule
segments apparently through a decrease in the activity of
both apical transporters and basolateral Na/K-ATPases
(Ortiz and Garvin 2002). Likewise, Villarreal et al (2004)
found that chronic inhibition of NO synthesis impairs the
acute leptin-mediated natriuretic effect in normotensive lean
rats. The kidney has been shown to express high amounts
of leptin receptors (Serradeil-Le Gal et al 1997), yet it is
not clear whether leptin evokes a direct effect on leptin
receptors or indirectly via induction of NO release in renal
tubules.
Interestingly, the short-term leptin-induced natriuretic
effect seen in lean animals was attenuated in obese rats and
was even blunted in spontaneously hypertensive rats (SHR)
(Villarreal et al 1998; Beltowski, Wojcicka, Gorny, et al
2002). This suggests a certain level of peripheral leptin
resistance, probably as a result of several factors including
renal receptor down-regulation induced by long-standing
hyperleptinemia (Coatmellec-Taglioni et al 2003) and/or the
presence of chronic antinatriuretic mechanisms, typical of
these states, such as an enhanced RSNA and renin–
angiotensin system (Villarreal et al 1998; Beltowski,
Wojcicka, Gorny, et al 2002), which may have overcome
leptin-mediated natriuresis. In agreement with this statement,
Villarreal et al (2000) found that SHR after renal denervation
recovered the sodium excretory capacity in response to acute
leptin administration.
Chronic effects
Conversely, long-term leptin administration increases both
RSNA and blood pressure. Recent data indicate that chronic
hyperleptinemia decreases natriuresis and urinary excretion
of NO metabolites (NOx) (Beltowski, Jamroz-Wisniewska,
et al 2004). In humans, a negative correlation between leptin
and NOx was observed recently in obese hypertensive
individuals (Golan et al 2002). Apparently, long-term
hyperleptinemic states like obesity increase the level of
systemic and intrarenal oxidative stress, leading to NO
deficiency (Beltowski, Wojcicka, et al 2004). Leptin,
chronically, would reduce natriuresis by up-regulation of
the Na/K-ATPase pump, especially in the renal medulla,
thereby promoting sodium retention (Beltowski, Jamroz-
Wisniewska, et al 2004). This antinatriuretic response to
chronic hyperleptinemia, could be either secondary to renal
sympathetic activation (Echtenkamp and Dandridge 1989;
Kirchheim et al 1989; Beach 1992) and/or deficiency of
systemic and intrarenal NO production (Beltowski,
Wojcicka, et al 2004). Chronic inhibition of NO synthesis
in the renal medulla may reduce medullary blood flow by
30%, which is associated with sodium retention and high
blood pressure (Mattson et al 1994).
Supporting these observations, Bickel et al (2001)
reported an increased number of different sodium tubular
transporters in the kidney of obese rats. These animals
exhibited a decreased natriuretic effect after a saline load
when compared with their lean age mates. In addition,
thiazide-sensitive Na/Cl cotransporters’ abundance has been
shown to be associated with inhibition of NO synthesis.
Clinical relevance
Chronic hyperleptinemia, as mentioned, augments the blood
pressure by means of different mechanisms in animal
models. In humans, there have been several studies
attempting to link leptin to hypertension (Figure 1). Serum
leptin levels are elevated in obesity due to increase amount
of adipose tissue which is the main source of the hormone
and possibly secondary to some degree of central resistance
to its action. A number of studies have found leptin to be
positively correlated with systolic and diastolic blood
pressure in both obese (Kunz et al 2000; Golan et al 2002;
Itoh et al 2002; Al-Hazimi and Syiamic 2004; Canatan et al
2004a; Schutte et al 2005) and non-obese individuals
(Uckaya et al 1999; Adamczak et al 2000; Takizawa et alVascular Health and Risk Management 2006:2(2) 166
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2001; Barba et al 2003; Canatan et al 2004b). Al-Hazimi
and Syiamic (2004), for example, found that serum leptin
and angiotensin II levels were strong predictors of elevated
blood pressure in obese women. Likewise, other
investigators (Kunz et al 2000; Golan et al 2002; Canatan
et al 2004b) reported higher leptin levels in obese
hypertensives compared with obese normotensive
individuals, even after controlling for confounders such as
age and body mass index (BMI). In another study leptin
correlated stronger with systolic and diastolic blood pressure
than did with BMI (or waist circumference) in untreated
male adults (Barba et al 2003). Moreover, one study found
that after a 3-month weight reduction program, leptin
continued to correlate positively with mean arterial blood
pressure in the hypertensive, but not in the normotensive
obese group (Itoh et al 2002). Interestingly, leptin has been
found to be elevated in several hypertensive states of
pregnancy as well (Anato et al 2000; Vitoratos et al 2001).
For instance, Vitoratos et al (2001) reported increased leptin
levels in pre-eclamptics compared with normotensive
pregnant women of the same gestational age. Of note is
also the observation that a positive correlation between leptin
and platelet count levels exist in pre-eclamptic women
(Anato et al 2000).
In disagreement to some of these data, one study found
that leptin levels were higher in hypertensives than in
Figure 1 Renal and blood pressure effect of leptin.  Adapted from Hall et al 2001. Copyright © 2001. Reproduced with permission from Hall JE, Hildebrandt DA, Kuo
J. 2001. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertension, 14(6 Pt 2):103S-115S.
5HQDODQG%ORRG3UHVVXUH(IIHFWRI/HSWLQ
2EHVLW\
6HOHFWLYH/HSWLQ
5HVLVWDQFH
/HSWLQ
(QGRWKHOLDO
'\VIXQFWLRQ
1LWULF2[LGH 6\PSDWKHWLF
$FWLYLW\
5HQDO1D
5HDEVRUSWLRQ
%ORRG3UHVVXUH

"
 Vascular Health and Risk Management 2006:2(2) 167
Leptin and hypertension in obesity
normotensive African Americans, but once these individuals
were adjusted for obesity, no significant relationship was
further observed between leptin and blood pressure (El-
Gharbawy et al 2002).
In summary, it seems evident that serum leptin levels
are significantly elevated in obese hypertensive individuals
when compared with obese normotensives. However this
relationship between leptin and blood pressure may not
always be as evident after controlling for BMI in some
subjects, making the assumption of leptin as a one of the
potential causes of hypertension in obesity, less consistent.
Possible treatment considerations
The elevated leptin concentrations seen in obese hypertensive
humans are mainly due to abdominal adipose tissue secretion.
Current studies have elucidated that some antihypertensives
might be more relevant than others in terms of reducing leptin
levels in obesity. For example, angiotensin II has recently been
found to stimulate leptin production in human adipose tissue
(Skurk et al 2005), possibly by means of activation of the
angiotensin II type 1 receptor subtype. This effect was
completely abolished when the angiotensin receptor blocker
(ARB) candesartan was employed prior to angiotensin II
administration in human fat cells. In agreement with this
observation, valsartan, another ARB, aside from lowering blood
pressure, decreased leptin levels and BMI in obese individuals,
when compared with the calcium channel blocker (CCB)
felodipine (Fogari et al 2005). Similarly, the angiotensin-
converting enzyme (ACE) inhibitor, enalapril, in combination
with a weight reduction program, evidenced the greatest
benefits in terms of weigh loss and diminution of plasma
norepinephrine, insulin, and leptin levels in comparison with
control groups treated with weight reduction program alone or
combined with the CCB amlodipine (Masuo et al 2001). In
another study, the beta-blocker (BB) pindolol showed a marked
suppressive effect on serum leptin levels, not seen in
hypertensive individuals on perindopril, or felodipine (Ficek
et al 2002).
In contrast to these findings, Sonmez et al (2001) in an
earlier study, found no clear effect of the ARB Losartan on
leptin levels in young hypertensive individuals despite its
hypotensive action. Likewise, both enalapril and clonidine
reduced heart sympathetic activity and blood pressure in
another clinical trial, but failed to decrease serum leptin
levels in normotensive obese and non-obese subjects after
7 days of treatment (Amador et al 2004).
It is worth mentioning that obesity is associated with
sodium retention and increased extracellular volume
inducing hypervolemia and increased cardiac output,
leading to the activation of the renin–angiotensin and
sympathetic nervous system; all of these factors
contributing ultimately to the development of
hypertension and eccentric-concentric left ventricular
hypertrophy: changes that may induce congestive heart
failure, arrhythmia, and sudden death (Figure 2) (Zhang
and Reisin 2000).
Although the studies are not yet consistent, it seems that
pharmacologic suppression of the sympathetic nervous
system, the renin–agiotensin system and, lately
hyperleptinemia with ACE inhibitors, ARB and BB, may
resemble the blood pressure reduction effect induced by
weight loss. Diuretics, on the other hand, by eliminating
urinary sodium and extracellular fluid, might also play a
significant role in the treatment of hypertension in obesity,
as these individuals are known for being sodium retainers
and hypervolemics. Nevertheless, BBs and diuretics may
affect insulin sensitivity and cause hyperglycemia and so
their use should be carried out with close monitoring of
glycemia in this patient population.
Summary
In summary, leptin the adipose tissue-derived hormone
by way of distinct neurochemical pathways stimulates
sympathetic nerve activity in thermogenic and
nonthermogenic tissue, affecting the metabolic and
cardiovascular system respectively. Leptin, acutely, could
have a dual influence on blood pressure control, in which
the net effect would depend on the balance between the
pressor action through activation of the sympathetic
nervous system and a possible natriuretic and peripheral
vasorelaxant effect of the hormone on the renal tubules
and endothelium. In contrast, chronic hyperleptinemia
may lead to abnormal renal sodium retention and
vasoconstriction associated with renal sympathetic
activation and NO deficiency, both contributing to
pressure elevation in obese individuals, who may develop
resistance to the satiety effect of leptin with preservation
of the cardiovascular effect. Treatment of these
individuals might be focused in overcoming the
hemodynamic alterations seen in obesity, such as
antinatriuresis and overactivity of the sympathetic and
renin–angiotensin systems.Vascular Health and Risk Management 2006:2(2) 168
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